Literature DB >> 31059044

CD47 deficiency protects cardiomyocytes against hypoxia/reoxygenation injury by rescuing autophagic clearance.

Yong Li1, Kun Zhao1, Pengyu Zong1, Heling Fu2, Yuan Zheng2, Dan Bao2, Yuan Yin2, Qin Chen2, Lu Lu2, Youjin Dai2, Daorong Hou2, Xiangqing Kong1.   

Abstract

To assess the effect of cluster of differentiation (CD47) downregulation on autophagy in hypoxia/reoxygenation (H/R)‑treated H9c2 cardiomyocytes. H9c2 cells were maintained in normoxic conditions (95% air, 5% CO2, 37˚C) without CD47 antibodies, Si‑CD47 or chloroquine (CQ) treatment; H9c2 cells in the H/R group were subjected to 24 h of hypoxia (1% O2, 94% N2, 5% CO2, 37˚C) followed by 12 h of reoxygenation (95% air, 5% CO2, 37˚C). All assays were controlled, triplicated and repeated on three separately initiated cultures. The biochemical parameters in the medium supernatant were measured to evaluate the oxidative stress in cardiomyocytes. The Annexin V‑fluorescein isothiocyanate assay was used to detect the apoptotic rate in the H9c2 cells. Transmission electron microscope, immunofluorescent staining and western blot analysis were performed to detect the effect of the CD47 antibody on autophagic flux in H/R‑treated H9c2 cardiomyocytes. The cardiomyocytic oxidative stress and apoptotic rate decreased and autophagic clearance increased after CD47 downregulation. H/R triggered cell autophagy, autophagosome accumulation and apoptosis in H9c2 cell lines. However, these effects can be attenuated by CD47 downregulation. This study demonstrates its clinical implications in ischemia/reperfusion injury treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31059044     DOI: 10.3892/mmr.2019.10199

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

Review 1.  Emerging Therapeutic Targets for Heart Failure.

Authors:  Maneesha Sharma; Lokesh Kumar Bhatt
Journal:  Curr Cardiol Rep       Date:  2022-10-04       Impact factor: 3.955

2.  CD47 antibody protects mice from doxorubicin-induced myocardial damage by suppressing cardiomyocyte apoptosis.

Authors:  Yan Hao; Lianghua Chen; Zhilong Jiang
Journal:  Exp Ther Med       Date:  2022-03-24       Impact factor: 2.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.